TEAD inhibition for individualized treatment of advanced head and neck squamous cell carcinoma stratified by YAP/TAZ transcriptional activity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038765

Enrollment

Registered

2025-12-22

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Squamous Cell Carcinoma C01 C02 C03 C04 C05 C06 C09 C10 C12 C13

Interventions

Group 1: Adult patients with head and neck squamous cell cancer who undergo medically indicated surgical tumor resection will be prospectively enrolled in this study. The study is non-interventional

no study-related therapeutic or diagnostic interventions, randomization, or blinding are performed. Clinical management and treatment decisions remain entirely independent of study participation and f

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: written informed consent, histopathologically confirmed HNSCC, German-speaking

Exclusion criteria

Exclusion criteria: Minors, no consent, non-surgical treatment

Design outcomes

Primary

Measure	Time frame
To measure and characterize YAP/TAZ activity across HNSCC patient samples and cellular models to predict sensitivity to TEAD inhibition, we want to specifically address the following aims: I. Assessment of YAP/TAZ transcriptional activity across HNSCC patients and HNSCC cell line panels. II. Generation and molecular characterization of HNSCC patient-derived organoid models and testing of sensitivity to TEAD inhibition. III. Genome-wide CRISPR/Cas9-based functional genetic screen for genes affecting sensitivity of HNSCC cell lines to TEAD inhibition.	—

Measure

Time frame

To measure and characterize YAP/TAZ activity across HNSCC patient samples and cellular models to predict sensitivity to TEAD inhibition, we want to specifically address the following aims: I. Assessment of YAP/TAZ transcriptional activity across HNSCC patients and HNSCC cell line panels. II. Generation and molecular characterization of HNSCC patient-derived organoid models and testing of sensitivity to TEAD inhibition. III. Genome-wide CRISPR/Cas9-based functional genetic screen for genes affecting sensitivity of HNSCC cell lines to TEAD inhibition.

—

Countries

Germany

Contacts

Public ContactSebastian Dieter

Nationales Centrum für Tumorerkrankungen

sebastian.dieter@med.uni-heidelberg.de+49 6221 56 4801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026